Clinical Trial

Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis

Name: Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis — clinical trial record (NCT06951971)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

This study is trying to evaluate the efficacy and safety of dose-modified Emapalumab and Ruxolitinib (E-Ru) regimens for the treatment of active hemophagocytic lymphohistiocytosis.

Trial Details

NCT Number	NCT06951971
Lead Sponsor	The First Affiliated Hospital of Soochow University
Conditions	Hemophagocytic Lymphohistiocytosis (HLH)
Enrollment	30 participants
Start Date	2025-06-01
Primary Completion	2027-06-01 (estimated)
Study Completion	2028-06-01 (estimated)
Updated on ClinicalTrials.gov	2025-04-30